KRAS G12C Inhibitor Sotorasib (Lumakras) May Offer Long-Term Clinical Benefit in Patients with Non-Small Cell Lung Cancer (NSCLC); Two-Year Follow Up of CodeBreaK 100 Clinical Trial Demonstrated Prolonged Tumor Responses and Favorable Safety Profile; Results Reported at AACR Annual Meeting

Patients with non-small cell lung cancer (NSCLC) treated with the KRAS G12C inhibitor sotorasib (Lumakras) had a two-year overall survival rate of 32.5 percent, according to data from the CodeBreaK 100 clinical trial presented during the AACR Annual Meeting 2022, held April 8-13 in New Orleans. Based on the primary analysis from this trial, the U.S. Food and Drug Administration approved sotorasib in May 2021 for the treatment of patients with locally advanced or metastatic NSCLC whose tumors harbor the KRAS G12C mutation and who have received prior therapies. “Longer-term follow-up data are important to better define the safety and efficacy of sotorasib because it is the first-in-class KRAS G12C inhibitor therapy to be approved for this patient population,” said presenter Grace K. Dy, MD, Chief of Thoracic Oncology and Professor of Oncology at Roswell Park Comprehensive Cancer Center, Buffalo, New York. “For this particular analysis, we also sought to determine whether there are potential biomarkers that can identify patients who will derive long-term benefit from sotorasib treatment.”

Login Or Register To Read Full Story